Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, FL, USA.
J Transl Med. 2018 Aug 13;16(1):223. doi: 10.1186/s12967-018-1592-6.
Circulating exosomes from prostate cancer (PCa) patients undergoing radiotherapy are attractive candidate biomarkers for monitoring treatment response. Multiple workflows for isolation and content characterization of exosomes in biofluids have been attempted. We report a protocol to isolate and characterize exosomal miRNAs content and assess radiation-induced changes.
In this pilot study, we performed targeted exosomal miRNA profiling of 25 serum samples obtained from PCa patients with intermediate- and high-risk disease treated with curative radiotherapy (RT), and controls. Post-treatment blood samples were collected at least 28 days after radiation therapy as a paired follow-up sample. The complete workflow consisted of two phases: I) filtration and polyethylene glycol salt precipitation phase which enriched particles below 200 nm in size followed by characterization using electron microscopy, and II) flow cytometry. Finally, miRNA expression analysis between untreated and treated patient samples was performed using RNA extraction kit, and qRT-PCR.
In our preliminary data, 1 ml of serum from PCa patients showed higher exosomal concentration (3.68E+10) compared to controls (6.07E+08). The overall expression of exosomes after RT was found to be higher compared to untreated samples; the median value changed from 3.68E+10 to 5.40E+10; p = 0.52. Using electron microscopy, we were able to visualize cup-shaped vesicles with morphology and size compatible with exosomes. The bead-based flow cytometry showed positivity for exosomal tetraspanins surface markers CD63 and CD9. All five miRNAs (hsa-let-7a-5p, hsa-miR-141-3p, hsa-miR-145-5p, hsa-miR-21-5p, hsa-miR-99b-5p) have been identified in exosomes. Despite overall changes in hsa-let-7a-5p expression after radiation, the difference was significant only in the high-risk group (p = 0.037). In addition, the radiation response to hsa-miR-21-5p was elevated in the high-risk group compared to the intermediate group (p = 0.036).
Herewith, we demonstrated a protocol for isolation of serum exosomes and exosomal miRNA amplification. The recovery of exosomal miRNAs and their differential expression after radiation treatment suggests promising biomarker potential that requires further investigation in larger patient cohorts.
接受放疗的前列腺癌(PCa)患者的循环外泌体是监测治疗反应的有吸引力的候选生物标志物。已经尝试了多种用于分离和分析生物流体中外泌体内容物的工作流程。我们报告了一种分离和表征外泌体 miRNA 含量并评估辐射诱导变化的方案。
在这项初步研究中,我们对 25 名接受根治性放疗(RT)治疗的中高危疾病的 PCa 患者和对照组的血清样本进行了靶向外泌体 miRNA 分析。在放疗后至少 28 天采集治疗后的血液样本作为配对随访样本。完整的工作流程包括两个阶段:I)过滤和聚乙二醇盐沉淀阶段,该阶段富集粒径小于 200nm 的颗粒,然后使用电子显微镜进行表征,以及 II)流式细胞术。最后,使用 RNA 提取试剂盒和 qRT-PCR 对未处理和处理患者样本之间的 miRNA 表达分析。
在我们的初步数据中,与对照组(6.07E+08)相比,来自 PCa 患者的 1ml 血清中显示出更高的外泌体浓度(3.68E+10)。与未处理样本相比,RT 后外泌体的总体表达更高;中位数从 3.68E+10 变为 5.40E+10;p=0.52。使用电子显微镜,我们能够可视化具有与外泌体兼容的形态和大小的杯状囊泡。基于珠子的流式细胞术显示外泌体四跨膜蛋白表面标志物 CD63 和 CD9 呈阳性。在 exosomes 中已经鉴定出所有五个 miRNA(hsa-let-7a-5p、hsa-miR-141-3p、hsa-miR-145-5p、hsa-miR-21-5p、hsa-miR-99b-5p)。尽管 hsa-let-7a-5p 的表达在辐射后发生了总体变化,但仅在高危组中差异具有统计学意义(p=0.037)。此外,与中危组相比,高危组中 hsa-miR-21-5p 的辐射反应升高(p=0.036)。
本研究证明了分离血清外泌体和外泌体 miRNA 扩增的方案。外泌体 miRNA 的回收及其在辐射治疗后的差异表达表明具有有前途的生物标志物潜力,需要在更大的患者队列中进一步研究。